Technology
Dimerix unveils ‘tremendous’ top-line results for lead drug in treating rare kidney disorder – Small Caps
Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often leads to end-stage ki…
Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often leads to end-stage kidney failure.
Dimerix received orphan drug designation for DMX-200 in November 2018 in both the US and Europe for the treatment of FSGS, after repurposing the drug based on preliminary non-clinical data which showed a reduction in the numbe…
-
Noosa News13 hours agoMuster Dogs favourite Frank Finger makes final on-screen appearance with kelpie Annie in portrait show
-
Business11 hours agoShould we be paying more attention to these two rocketing ASX small-cap mining stocks?
-
Noosa News13 hours agoWhy commuters are less likely to see familiar strangers on the bus, train or CityCat and why that makes us feel less safe
-
General22 hours agoJapan and Australia urge calm after Chinese radar locks onto Japanese jets